#USA #New York #Pomerantz LLP #NGNE #Neurogene Inc.

Shareholder Alert: Pomerantz Law Firm Investigates Claims for Neurogene Inc. Investors

On January 28, 2025, Pomerantz LLP announced that it is conducting an investigation concerning claims on behalf of investors of Neurogene Inc. (NASDAQ: NGNE). This investigation focuses on potential securities fraud and other unlawful practices allegedly engaged in by Neurogene and certain of its officials and directors.

The inquiry comes in light of a significant event that has raised concerns among investors. On November 11, 2024, Neurogene released interim clinical data from their ongoing Phase 1/2 trial, which aimed to evaluate NGN-401 gene therapy for young female patients suffering from Rett syndrome. While the company portrayed the provided data as "positive," they mentioned that one of the two patients given a high dose experienced a serious treatment-related adverse event—a detail that contradicted the optimistic outlook Neuogene initially projected. This revelation sparked an immediate negative response in the stock market, with the share price plunging by 44.08%, closing at $40.00 on November 12, 2024.

The situation deteriorated further when, on November 18, 2024, Neurogene issued an update indicating that the patient previously mentioned was now in critical condition. The company also announced revised expectations regarding the enrollment process for the low-dose cohort of the trial, admitting they would not be able to complete this process within the projected timeframe of the fourth quarter of 2024. The immediate effect of this news significantly impacted Neurogene’s stock price, which fell steeply during intraday trading on the same day.

Pomerantz LLP, a well-established firm known for its expertise in corporate and securities litigation, particularly class actions, has a long history of representing aggrieved investors. Founded by renowned attorney Abraham L. Pomerantz, the firm has been instrumental in advancing the rights of those impacted by securities fraud and corporate misconduct for over 80 years. With offices located in key cities such as New York, Chicago, Los Angeles, London, and Paris, Pomerantz LLP is acknowledged as a leader in its field, having secured substantial compensatory awards for victims of securities malpractice.

Investors who believe they may have been affected by these recent developments at Neurogene Inc. are encouraged to reach out to the firm for inquiries related to joining a potential class action lawsuit. Danielle Peyton, an attorney at Pomerantz, can be contacted at [email protected] or 646-581-9980, ext. 7980. The investigation aims to shed light on the possible misrepresentations made by the company, the impact on its stock, and whether Neurogene's leadership has acted in the best interest of its shareholders.

As the healthcare and biotechnology sectors grow increasingly complex, safeguarding investor rights remains a critical focus. This ongoing investigation by Pomerantz LLP is a reminder of the vital importance of transparency and accountability from publicly traded corporations, especially those involved in such crucial healthcare advancements. Stakeholders and potential investors should follow developments closely as the situation unfolds.

For more information about the investigation and updates regarding investor rights, visit Pomerantz Law Firm's website. Please note that past outcomes do not guarantee future results, and this investigation is solely focused on gathering information for those impacted by the recent events surrounding Neurogene Inc.